Interferon alpha-2b in comprehensive treatment of patients with COVID-19
Objective. To evaluate the efficacy and safety of human recombinant interferon alpha-2b (VIFERON®) as a part of comprehensive treatment for coronavirus infection COVID-19.
Patients and methods. This prospective, comparative, controlled study included 140 patients with COVID-19 randomized in two groups. The experimental group (EG) included 70 patients who received standard therapy plus VIFERON® (one rectal suppository 3,000,000 IU three times a day and gel 36,000 IU/g 5 times a day applied to the nasal mucosa and palatine tonsils for 14 days); the control group (CG) comprised 70 patients who received standard therapy alone.
Results. Patients in the EG demonstrated more rapid resolution of main symptoms, such as intoxication, bronchopulmonary and catarrhal manifestations. Normalization of the total score in the EG was observed 7 days earlier than in the CG. In the EG, the proportions of patients who had their D-dimer and CRP levels normalized were 42.7% and 18.7% higher than those in the CG, respectively (р < 0.05). Follow-up computed tomography demonstrated that the proportion of patients with positive dynamics in the EG was 8.1% higher than that among controls, whereas advanced disease with 51%–75% of lung tissue affected was 11.9% less common in participants from the EG than in controls (р = 0.019). We observed no adverse events associated with interferon alpha-2b (VIFERON®) or other medicines included in the treatment scheme.
Conclusion. Our findings suggest high efficacy and safety of recombinant interferon alpha-2b (VIFERON®) used in combination with symptomatic agents, antibiotics, anticoagulants, which allows us to recommend this drug for inclusion into standard treatment schemes for COVID-19.
Key words: COVID-19, coronavirus infection, human recombinant interferon alpha-2b
For citation: Mordyk A.V., Ivanova O.G., Samsonov K.Yu., Sitnikova S.V., Zenkova L.A. Interferon alpha-2b in comprehensive treatment of patients with COVID-19. Infekc. bolezni (Infectious diseases). 2021; 19(1): 16–25. (In Russian). DOI: 10.20953/1729-9225-2021-1-16-25